"New Malaria Vaccine Shows High Protection in African Children"

A malaria vaccine developed by the University of Oxford and the Serum Institute of India has shown to prevent around three-quarters of symptomatic malaria cases in young children in a large trial, with results published in The Lancet medical journal. The vaccine, known as R21, is the second to become available this year and has already been approved for use in three West African countries and by the World Health Organization. The vaccine is cheaper and more readily available than the first vaccine, and there are plans to provide further updates as more countries express demand.